Handheld Volumetric Capnography (Lumetry) 用于 COPD 患者家庭监测
Handheld volumetric capnography (Lumetry) for carbon dioxide monitoring in advanced COPD
一项单中心前瞻性研究评估了手持式容积二氧化碳监测设备 Lumetry 在 COPD 患者中的安全性和准确性。研究结果显示,Lumetry 在平静呼吸时轻度低估了二氧化碳分压值,但在深呼吸时与动脉血气分析结果一致,且无安全问题。该设备适用于 COPD 患者的家庭监测,有助于早期发现高碳酸血症加重。
Abstract
Regular measurements of oxygen (O2) and carbon dioxide (CO2) are crucial for evaluation of the respiratory status in patients with moderate and advanced COPD. While O2 monitoring is well established by pulse oximetry, there are still no established methods for non-invasive home measurements of CO2 in patients during spontaneous breathing. Until now, patients must consult specialists or clinics for standardized procedures such as blood gas analysis (BGA) or transcutaneous capnometry (tCO2). We therefore investigated a new hand-held device (Lumetry), based on volumetric and spirometric capnography with modernized algorithms for COPD patients during calm, spontaneous breathing (exclusion criterion RR > 21/min) and optimized beathing maneuvers. The aim of the study was to assess (1) the safety and usability of Lumetry and (2) agreement with well-established measurement methods BGA und tCO2. In this single-center prospective study, electively admitted patients with COPD GOLD 3 or 4 underwent spirometric capnography CO2 measurements (petCO2). Patients were stratified according to presence of hypercapnia as defined by a daytime paCO2 >45 mmHg. End-tidal (petCO2) values were translated to pCO2 per device specific algorithms. Different breathing maneuvers (rested breathing, one deep exhalation, two deep in- and exhalations), were performed and the Lumetry results were compared with standardized CO2 procedures in capillary blood gas analysis (Siemens, RAPIDpoint 500) and transcutaneous CO2 measurement (Radiometer TCM5). Agreement between measurement methods were assessed using Bland-Altman analysis calculating mean bias and limits of agreement (LoA) 57 patients (32 women) were included in the analysis of whom 30 (52.6%) had hypercapnia. In the overall cohort, Lumetry slightly underestimated pCO2 values compared to capillary blood gas analysis (CBG) during rested breathing (mean bias 6.1 mmHg, 95% LoA − 2.6 to 14.8 mmHg). Best agreement was observed for the deep breath mean maneuver (bias 2.1 mmHg, LoA − 8.2 to 12.4 mmHg). When stratified by hypercapnia status, the same pattern was observed. Lumetry showed similar agreement to CBG when compared to standard transcutaneous CO2 levels (bias − 1.7 mmHg, LoA − 10.4 to 7.0 mmHg). There were no safety restrictions and the Lumetry device was easy to handle. Capnographic Lumetry measurements showed acceptable limits of agreement to capillary blood gas analysis. They furthermore proved non-inferior to transcutaneous CO2 measurements. Results were consistent in hypercapnic and non-hypercapnic COPD patients and optimized by adapted deep breathing maneuvers. The Lumetry device was safe and easy to use. These promising results highlight its potential for home-based CO2 monitoring and early detection of hypercapnic exacerbations.
Introduction
The assessment of respiratory status is an essential component in diagnostic, treatment and surveillance of chronic respiratory diseases. Whereas oxygen levels widely reflect gas exchange of the lungs (respiratory muscle overload), CO2 represents the ventilatory function (type 2 respiratory failure) and by so is an indispensable marker of hypoventilation and respiratory impairment. Despite this, monitoring of the ventilatory function remains a challenge to this date.
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease. The deterioration of respiratory function can lead to gas exchange disorders and is further aggravated by progressive weakness of the respiratory muscles and inflammation in the bronchi, causing alveolar hypoventilation. Hence, hypercapnia (PaCO2 >45 mmHg) is more common in severe forms of COPD, but can also be found in some patients with moderate disease. German registry data report 25% hypercapnia in patients with COPD GOLD 3 and 41. In these patients, hypercapnia is an independent risk factor of mortality and hospitalizations and is by so an important treatable trait2. Reduction of hypercapnia by non-invasive ventilation in hypercapnic COPD patients improves survival3. Regular CO2 measurement is by so highly desirable, possibly even in a home-based environment. Both of the to this date standardized methods of invasive (arterial/capillary blood gas analysis, ABG/CBG) and non-invasive (transcutaneous CO2, tCO2) measurement are limited to clinical and out-patient practice settings.
Arterial blood gas analysis (ABG) requires medical expertise, is time consuming, carries risks such as vessel damage and often painful for patients. Subsequently, arterialized capillary blood gas analysis (CBG) has been established in clinical practice since the 1960s and shows high correlation to arterial PaCO2 in healthy persons as well as COPD patients4. Earlobe sampling was shown to be more accurate than fingertip sampling5. Adequate vasodilation is essential to obtain reliable results.
Transcutaneous carbon dioxide (tCO2) measurement is a non-invasive, well established and accepted method, often combined with oxygen and pulse rate monitoring. It requires a steep learning curve and is prone to user and device induced failure – but is widely recognized as state of the art, especially in hypercapnic COPD patients6,7,8. It is to this date the only non-invasive method in use during spontaneous breathing. Elevated skin temperature (42–43°) is required to enhance blood flow and CO2 diffusion. Therefore, skin measured CO2 levels are generally higher than blood-based measurements due to heat induced cell metabolism9. Measurement quality also depends on skin thickness, metabolic processes and environmental factors such as temperature and humidity – but also vascularity and blood vessel tone. Modern devices implement additional algorithms to improve the approximation of PaCO2. Nevertheless, deviations between tCO2 and PaCO2 often remain, and transcutaneous measurement shows a significant difference compared to blood-based methods. While the bias of tCO2 to CBG is acceptably low, the limit of agreement can be quite wide10,11.
Drawbacks of tCO2 are a long calibration phase (10 min) and demanding equipment, prone to inaccuracies in routine daily use. This requires regular device training and is hardly accessible in an out-patient setting. During use exceeding 6 h, a drift in values may occur. Overcoming these disadvantages is a set goal with Lumetry.
End-tidal volumetric capnography (petCO2) has been used for years in patients undergoing invasive ventilation. CO2 is determined using infrared sensors, allowing an approximation of the alveolar concentration of CO2. However, the method is not as accurate as arterial blood gas analysis and also transcutaneous measurement10. There is, up to date, very little data concerning petCO2 measurements during spontaneous breathing – and previous results show disappointing outcomes10,12,13. Exhalation maneuvers can improve accuracy of estimation in COPD patients13. The Lumetry device combines spirometry and volumetric capnography with an advanced, non-dispersive infrared sensor and a new algorithm for calculation of pCO2 from end tidal CO2 in one device. This has potential to overcome well known impediments of currently used measurement techniques. We therefore investigated the novel held-hand device in patients with COPD during spontaneous breathing and optimized beathing maneuvers. The aim of the study was to assess (1) the safety and usability of the Lumetry device and (2) agreement between Lumetry CO2 and well-established CO2 measurement methods BGA und tCO2.
Materials and methods
Study design and setting
From June 2024 to March 2025 we conducted a single-center prospective observational cohort study in 60 patients with COPD GOLD 3–4. The study participants were admitted to Thoraxklinik University Clinic Heidelberg for treatment of COPD. They were in stable general condition. Written informed consent was acquired after evaluation of study eligibility criteria (Table S1). Among other things, an elevated resting respiratory rate (> 21/min) was an exclusion criterion. Respiratory rate was determined by manual counting. Participants were stratified into two groups by (daytime) CBA: hypercapnia (PaCO2 > 45 mmHg) and non-hypercapnia (PaCO2 < 45 mmHg). The study protocol was approved by the local ethics committee (DE-24-00015155) and is in accordance with the declaration of Helsinki.
Study device - Lumetry
The Lumetry device consists of two components: a NDIR (non-dispersive infrared ) sensor and a mass flow senor (PMF86200-B, manufactured by Posifa Technologies, San Jose CA; distributed by Pewatron AG, Germany). Both are embedded in breathe ilo 2.0 (Lumetry diagnostics GmbH), a breath analyzer device for determining women’s fertile days based on changes in end-tidal pCO2 values (medical device safety class I, CE certified, Fig. 1).
Lumetry device.
CO2 values are derived from the NDIR signal and are independent of flow measurements. Combined data of the flow sensor and the CO2 sensory system generate volumetric waveforms, which support spirometric parameters and enable more precise calculation of volumetric capnography (petCO2). An additional thermal anemometry (MS8607-02BA01 PHT Sensor – TE Connectivity) detects air temperature, pressure and humidity during each breathing maneuver. These parameters are taken into account during the following CO2 calculations. Lumetry device has been tested temperature stable at 15 °C to 30 °C. The Lumetry research device was pending CE certification during this study.
Calculation of petCO2 was performed during different breathing maneuvers. First, the entire measurement was divided into breaths, then averaged to form a master curve, which was specific for each patient. Breaths identified as irregular (e.g. coughing) were removed from the analysis (valid breaths, Table S2). Second, three different breathing maneuvers were executed: rested breathing, maximum exhalation and deep breathing. PetCO2 was obtained by arithmetic mean, maximum recorded value and mean of maximum values during deep breaths.
Capillary blood gas analysis (CBG)
CBG was obtained from the earlobe after arterialization by use of Nonivamide/Nicoboxil cream and after skin cleansing. The ointment was left on for a minimum of 10 min before the first blood sample was taken. Blood was sampled after documentation of tCO2 to account for sensor lag time. Collection was performed after ear prick by capillary tube (Muticap-S, Siemens Healthcare Diagnostics) and measured by the blood gas system (RAPIDPoint 500e, Siemens Healthineers).
Transcutaneous carbon dioxide monitoring (tCO2)
TCO2 was measured by a TCM 5 flex transcutaneous monitor (Radiometer GmbH Germany) via heated (43 °C) electrode and pulse oximetry sensor clipped to the contralateral earlobe. The skin was previously cleaned with isopropanol (70%) and then dried. A drop of sensor gel was applied to the center of the membrane surface. As recommended by the manufacturer, the electrode was calibrated beforehand in the docking station and the sensor membrane was changed every 2 weeks. After application, the sensor was allowed 10–15 min of calibration before measurement documentation.
Lumetry procedure
The patient was placed in a relaxed, upright position in bed. Arterializing cream was applied to one earlobe and the TCM sensor was applied to the contralateral earlobe. During explanation of the breathing procedure, the patient’s breathing rate at rest obtained (exclusion criterion breathing rate > 21/minute) and stored in the Lumetry device.
For hygienic reasons in this study, only the mouthpiece came into direct contact with the patients. Mouthpieces were single use and supplemented by standard air filter (MicroGard™ II PFT Filter). Existing oxygen therapy was removed. Simultaneously a single use nose clip was placed to ensure only mouth breathing and the mouthpiece was enclosed, thus starting the measurement. The stored patient’s resting frequency was activated and signaled acoustically and visually via app the intended breathing rate (guided breathing maneuver). This procedure was performed for 20 s.
Next, the Lumetry measurement was started. Data was collected during 45 s of rested breathing (petCO2 rest). After 30 s tCO2 was documented and capillary blood gas analysis (CBG) from the ear lobe was performed. The procedure ended by one calm, long exhalation to (preferably) residual volume (Figure S3, petCO2 max).
After 5 min rest, the second breathing procedure was initiated. If required, a phase of guided breathing was started (by patient’s decision). Otherwise, measurement was immediately started by rested breathing. After 30 s, tCO2 was documented and deep breathing was initiated: two calm, maximum deep inhalations and exhalations (Figure S4, pet CO2 deep), ending at (preferably) expiratory residual volume. A mean value was calculated from both (petCO2 mean). The second CBG was collected during deep breathing. An overview of CO2 values is shown in Table S5. A flowchart of the examination procedure can be found in Figure S6.
The device was operated using a smartphone app adapted for the study. Upon test completion, the raw data (including flow, pressure, and CO₂ waveforms) was transmitted to a cloud-based backend system, processed by the Lumetry algorithm and the results subsequently sent back to the clinical experts. Invalid measurements were reported to medical/study staff (Table S7).
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and categorical variables as absolute and relative frequencies (n, %). Comparisons between groups were performed using Chi-square tests for categorical variables and paired t-tests for continuous variables, respectively. Agreement between measurement methods and reproducibility were assessed using Bland-Altman analysis. For each pair of measurements, the mean difference (bias) and the 95% limits of agreement (LoA, mean difference ± 1.96 × SD) were calculated [PMID: 2868172]. We intended to include 60 participants, comprising approximately equal numbers of patients with and without hypercapnia. Sample size calculation was based on an expected difference of 2 ± 4 mmHg between measurement methods in patients without hypercapnia. Inclusion of 27 patients per group would provide 95% statistical power to detect this difference at a two-sided alpha level of 0.05 using paired t-test. A multivariable linear regression model was fitted to identify independent determinants of measurement bias. Receiver operating characteristic (ROC) analyses were performed to assess the ability of Lumetry measurements to discriminate between hypercapnic and non-hypercapnic patients. Area under the curve (AUC), optimal thresholds, sensitivity, and specificity were calculated. All statistical analyses were performed using R (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). [R Core Team (2025). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/]
Results
60 patients were screened for study inclusion. A total of 57 patients were included in the analysis of whom 30 (52.6%) had hypercapnia and 27 (47.4%) did not. Two patients of the initially screened cohort were excluded due to withdrawn consent. In one patient Lumetry data was insufficient due to WLAN difficulties. The study population consisted of 32 women (56.1%) and 25 men (43.9%), with a mean age of 67.4 ± 8.4 years. Details on baseline characteristics are provided in Table 1. No complication occurred with any of the devices. Bland-Altmann analysis was performed to assess the agreement between Lumetry and blood gas analysis and tCO2.
Comparison of Lumetry CO2 and capillary blood gas analysis PaCO2
Across the overall cohort, Lumetry slightly underestimated pCO₂ values compared with BGA during rested breathing, with a mean bias of 6.1 mmHg (95% LoA − 2.6 to 14.8 mmHg, (Fig. 2).
Comparison of Lumetry CO2 (rested breathing) and CBG, overall.
When stratified by hypercapnia, the bias was 4.7 mmHg in patients without hypercapnia and 7.3 mmHg in those with hypercapnia, with broader limit of agreement (LoA) in the latter (-2.1 to 16.6 mmHg vs. -2.4 to 11.8 mmHg, respectively; Fig. 3).
Comparison of Lumetry CO2 (rested breathing) and CBG, subgroups hypercapnia and non-hypercapnia.
These findings indicate good overall agreement between the two methods, while suggesting slightly greater measurement variability at higher pCO₂ levels.
We further analyzed the data obtained during different breathing maneuvers. For Lumetry pCO₂ derived from the maximum breath, BGA measurements tended to yield slightly higher pCO₂ values, with a negative mean bias of -5.0 mmHg (LoA − 12.7 to 2.7 mmHg). Based on the work of Lujan et al., we also supplemented a mean value between Lumetry in rested respiration and maximal breath, stratified against pCO2. In our study, this did not improve the agreement of method.
In contrast, the agreement was markedly better when using the deep breath mean signal (Fig. 4), which showed a small positive bias of 2.1 mmHg and narrower LoA (-8.2 to 12.4 mmHg).
Comparison of Lumetry CO2 (deep breathing mean) and CBG, overall.
When stratified by hypercapnia status, the same pattern was observed (hypercapnia bias 2.0, LoA − 8.7 to 12.7 mmHg; non-hypercapnia bias 2.2 mmHg, LoA − 8.1–12.4 mmHg) (Fig. 5).
Comparison of Lumetry CO2 (deep breathing mean) and CBG, subgroups hypercapnia and non-hypercapnia.
The deep-mean approach produced highly consistent results across the entire pCO₂ range and between hypercapnic and non-hypercapnic patients in contrast to results during breathing rest and max and also mean value of both. These findings indicate that pCO₂ estimation based on the deep-breath mean provides the most robust and reliable agreement with capillary blood gas measurements during the deep-breath maneuver.
Comparison of Lumetry CO2 and transcutaneous CO2
When comparing transcutaneous CO₂ measurements with Lumetry at rest, the agreement between both methods was limited. Overall, tCO2 values were systematically higher than those obtained with Lumetry, with a mean bias of 7.5 mmHg and wide limits of agreement (-12.3 to 17.3 mmHg). After stratification by hypercapnia status, the overestimation persisted in both subgroups, with mean biases of 5.2 mmHg in participants without hypercapnia and 9.7 mmHg in those with hypercapnia, suggesting that the discrepancy between both techniques increases at higher pCO₂ levels.
Comparison of transcutaneous CO2 and capillary blood gas analysis (CBA) PaCO2
In order to better classify Lumetry’s results, we supplemented comparison between PaCO2 in CBA to transcutaneous CO2 levels in this study. This showed acceptable agreement, similar to Lumetry, with a small positive bias of 1.7 mmHg and LoA (-10.4 to 7.0 mmHg).
Univariate analysis
As the best agreement with BGA was observed for the Lumetry deep mean measurement in both hypercapnic and non-hypercapnic patients, subsequent univariate analyses were focused on this measurement. In univariate analyses, the mean measurement bias did not differ significantly across sex, COPD severity or NIV use. The mean (± SD) bias was 1.5 ± 4.2 mmHg in females and 2.9 ± 5.1 mmHg in males (p = 0.39). Across COPD grades, the mean bias was 2.4 ± 4.2 mmHg in GOLD 3 and 1.8 ± 4.3 mmHg in GOLD 4 (p = 0.71). Patients receiving NIV showed a bias of 2.2 ± 5.0 mmHg, compared to 1.8 ± 4.6 mmHg in those without NIV (p = 0.80). We then performed multivariable linear regression including demographic, physiological, and disease-related variables. Only the absolute pCO₂ at baseline was significantly associated with the measurement bias (β = 0.44 mmHg per mmHg, p = 0.0018, adjusted R² = 0.22) while all other variables showed no significant effects (p > 0.05, Table S8), especially residual volume (RV).
Receiver operating characteristic (ROC) analyses were performed to assess the ability of Lumetry measurements to discriminate between hypercapnic and non-hypercapnic patients. Both Lumetry measurement approaches showed good discriminatory performance for the detection of hypercapnia. The AUC was 0.86 (95% CI 0.76–0.96) for resting measurements and 0.84 (95% CI 0.74–0.95) for the deep breathing mean measurement. Sensitivity was identical for both approaches (85.7%), whereas specificity was slightly higher for resting measurements (80.0% vs. 72.0%) (S9).
Lumetry compatibility
There were no adverse events during the Lumetry breathing maneuvers. During this study, participants were asked to rate necessity of home CO2 measurements and use of Lumetry in their own opinion. 51% would welcome home care capnometry. The use of Lumetry was predominantly (58%) perceived as not strenuous, 12% found it difficult to use and others noticed slight strain or no comment. Subsequently, 59% considered using it at home to be feasible, 9% did not. Others answered “maybe” or gave no comment.
Discussion
The purpose of this study was to test a new non-invasive capnography technology in terms of safety and usability and to compare CO2 levels with established methods of CO2 measurement such as capillary blood gas analysis and transcutaneous CO2. This is, to the author’s knowledge, the first study to examine a handheld spirometry-based capnography in hypercapnic and non-hypercapnic patients with COPD III-IV while spontaneous breathing. Patients with a high respiratory rate (> 21/minute) were formally excluded; however, in practice, no such cases occurred. Overall, Lumetry measurements showed good discriminatory performance for the detection of hypercapnia (AUC 0.86 (95% CI 0.76–0.96) rested breathing, 0.84 (95% CI 0.74–0.95) deep breathing mean).
Compared with CBG, measurements of petCO2 during rested breathing showed unsatisfactory results with a high bias of 6.1 mmHg and wide LoA (-2.6 to 14.8 mmHg). Further distribution to subgroups of hypercapnic and non-hypercapnic worsened values, thus underestimating pCO2 compared to CBG. Further analysis of breathing maneuver max (one maximum exhalation) did not show better results – as also the mean value of rest and max breathing, in contrast to the results of Lujan et al.13.
Analysis of CO2 values during the second breathing maneuver deep breaths (mean rate of two maximum inhalation and exhalation) showed much more encouraging results. Overall, the bias was smaller (2.1 mmHg) and LoA narrower (-8.2 to 12.4 mmHg). When stratified by hypercapnia status, the same pattern was observed (hypercapnia bias 2.0 mmHg, LoA − 8.7 to 12.7 mmHg; non-hypercapnia bias 2.2 mmHg, LoA − 8.1–12.4 mmHg).
Difficulties with this method were to be assumed due to pathophysiological processes such as dynamic hyperinflation and dead space ventilation. This study confirms the significant influence of optimized breathing maneuvers; future studies will further expand on this aspect.
Put into perspective with former studies, these results are very promising. Lermuzeaux et al.10 compared petCO2 with (arterial) PaCO2 in spontaneous breathing COPD patients, showing a bias of 17.1 mmHg and extremely wide LoA (-7.5 to 41.5 mmHg).
On the other hand, transcutaneous CO2, to date the only available non-invasive capnometry method, has known but accepted limitations. Previous literature has shown a bias of 4.5 mmHg in hypercapnic COPD subjects (LoA 13 mmHg) compared to CBG7, similar to tCO2 in this study (bias 1.7 mmHg and LoA − 10.4 to 7.0 mmHg). The Lumetry results are therefore well comparable with standard non-invasive method via tCO2.
Against this backdrop, the study results send a very positive signal for future CO2 measurements. The goal is to provide a method that can be used at home or other out-patient settings lacking capnometry devices, similar to pulse oximetry. It should not be understood as a quantitative supplement for CBG, but as an additional tool in the assessment of the ventilatory function – especially for patients at risk of or manifest hypercapnia. Rising CO2 levels may provide early indications of ventilatory exacerbations and help optimize therapeutic procedures. Further prospective studies in out-patient settings and exacerbation conditions are needed are needed to shed light on this aspect.
Several considerations should be taken into account when interpreting our results. First, the number of subjects was limited and data not fully complete in all subjects, due to individual measurement failure, especially in CBG. Second, the time of value documentation was not always the same, but within a reasonable time frame of 15–30 s. Third, Lumetry measurements were performed under study conditions instructed by academic staff. The reliability of measurements performed at home (e.g. fluctuating temperatures, motivation during measurements) is currently unclear. Fourth, the specific breathing maneuvers were performed only once each without repetition. Fifth, it must always be taken into account that all three CO2 measurement methods are subject to variable fluctuations—even the gold standard blood gas analysis. Therefore, assessment of the ventilatory status must always take comprehensive clinical factors and repeated CO2 measurements into account.
In light of these limitations, further research and data collection is necessary to support accuracy of Lumetry CO2 measurements before clinical or home use can be established.
Conclusion
Capnographic Lumetry measurements showed acceptable limits of agreement to capillary blood gas analysis in patients with advanced COPD. They furthermore proved non-inferior to transcutaneous CO2 measurements – to this date the only available non-invasive capnometry method during spontaneous breathing. Results were consistent in hypercapnic and non-hypercapnic COPD patients and optimized by adapted deep breathing maneuvers. The Lumetry device was safe and easy to use. These promising results support future evaluation of the Lumetry device in out-patient settings and highlight its potential for home-based CO2 monitoring and early detection of hypercapnic exacerbations, though further research is required.
Data availability
The datasets generated and analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.
Abbreviations
- ABG:
-
Arterial blood gas analysis
- BE:
-
Base excess
- BGA:
-
Blood gas analysis
- CBG:
-
Capillary blood gas analysis
- COPD:
-
Chronic obstructive pulmonary disease
- HCO3− :
-
Hydrogen carbonate
- LoA:
-
Limits of agreement
- mmHg:
-
Millimeter of mercury
- NDIR:
-
Non-dispersive infrared sensor
- O2 :
-
Oxygen
- PaCO2 :
-
Partial arterial pressure of carbon dioxide
- pCO2 :
-
Partial pressure of carbon dioxide
- petCO2 :
-
End tidal pressure of carbon dioxide
- PFT filter:
-
pulmonary fuction test filter
- pH:
-
Potential of hydrogen
- tCO2 :
-
Transcutaneous carbon dioxide
References
Dreher, M. et al. Prevalence Of Chronic Hypercapnia In Severe Chronic Obstructive Pulmonary Disease: Data From The HOmeVent Registry. Int. J. Chron. Obstruct Pulmon Dis. 14, 2377–2384 https://doi.org/10.2147/COPD.S222803 (2019) PMID: 31695357; PMCID: PMC6805244.
Csoma, B. et al. Hypercapnia in COPD: Causes, Consequences, and Therapy. J. Clin. Med. 11 (11), 3180. https://doi.org/10.3390/jcm11113180 (2022). PMID: 35683563; PMCID: PMC9181664.
Köhnlein, T. et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2 (9), 698–705. https://doi.org/10.1016/S2213-2600(14)70153-5 (2014). Epub 2014 Jul 24. PMID: 25066329.
Pitkin, A. D., Roberts, C. M. & Wedzicha, J. A. Arterialised earlobe blood gas analysis: an underused technique. Thorax 49 (4), 364–366. https://doi.org/10.1136/thx.49.4.364 (1994). PMID: 8202909; PMCID: PMC475372.
Zavorsky, G. S., Cao, J., Mayo, N. E., Gabbay, R. & Murias, J. M. Arterial versus capillary blood gases: a meta-analysis. Respir Physiol. Neurobiol. 155 (3), 268–279. https://doi.org/10.1016/j.resp.2006.07.002 (2007). Epub 2006 Aug 17. PMID: 16919507.
Deutsche Gesellschafft für Pneumologie und Beatmungsmedizin e.V. S3 Leitlinie: Nichtinvasive Beatmung als Therapie der chronischen respiratorischen Insuffizienz. Version V 1.3; 17.07.2024; https://register.awmf.org/de/leitlinien/detail/020-008
Cox, M. et al. Non-invasive monitoring of CO2 levels in patients using NIV for AECOPD. Thorax 61 (4), 363–364. https://doi.org/10.1136/thx.2005.051664 (2006). PMID: 16565270; PMCID: PMC2104599.
McVicar, J. & Eager, R. Validation study of a transcutaneous carbon dioxide monitor in patients in the emergency department. Emerg Med J.;26(5):344-6. (2009). https://doi.org/10.1136/emj.2007.055715. PMID: 19386868.
Bernasconi, S. et al. Recent Technologies for Transcutaneous Oxygen and Carbon Dioxide Monitoring. Diagnostics (Basel). 14 (8), 785. https://doi.org/10.3390/diagnostics14080785 (2024). PMID: 38667431; PMCID: PMC11049249.
Lermuzeaux, M. et al. Superiority of transcutaneous CO2 over end-tidal CO2 measurement for monitoring respiratory failure in nonintubated patients: A pilot study. J. Crit. Care. 31 (1), 150–156 (2016). Epub 2015 Sep 25. PMID: 26463320.
Stieglitz, S., Matthes, S., Priegnitz, C., Hagmeyer, L. & Randerath, W. Comparison of Transcutaneous and Capillary Measurement of PCO2 in Hypercapnic Subjects. Respir Care. 61 (1), 98–105. https://doi.org/10.4187/respcare.03917 (2016). Epub 2015 Dec 1. PMID: 26628564.
Rousselon, S. et al. Comparaison de la mesure de la PETCO(2) obtenue avec le Smart Capnoline™ avec la PaCO(2) en postopératoire de chirurgie cardiaque chez des patients intubés puis extubés [Comparison between ETCO₂ values measured by the Smart Capnoline™ and the PACO₂ in intubated then extubated postoperative cardiac surgery patients]. Ann. Fr. Anesth. Reanim. 30 (1), 13–16. https://doi.org/10.1016/j.annfar.2010.11.008 (2011). French. Epub 2010 Dec 28. PMID: 21190808.
Lujan, M. et al. Capnometry in spontaneously breathing patients: the influence of chronic obstructive pulmonary disease and expiration maneuvers. Med Sci Monit.;14(9):CR485-92. PMID: 18758420. (2008).
Funding
Open Access funding enabled and organized by Projekt DEAL. This research was supported by Lumetry Diagnostics GmbH (Nikolaiplatz 4, 8020 Graz, Austria), there is no grant number. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no financial relationships with the funders.
Author information
Authors and Affiliations
Dept of Pneumology and Critical Care Medicine,Thoraxklinik, University of Heidelberg, Heidelberg, Germany
Mavi Schellenberg, Frederik Trinkmann & Felix Herth
Dept of Internal Medicine, Pneumology, Sankt Vincentius Clinic Speyer, Speyer, Germany
Edwane Mbi-Etah
Thoraxklinik Universitätsklinik Heidelberg, Röntgenstrasse 1, 69126, Heidelberg, Germany
Mavi Schellenberg
Authors
- Mavi Schellenberg
- Edwane Mbi-Etah
- Frederik Trinkmann
- Felix Herth
Contributions
M.S. designed study, wrote main manuscript, performed measurements and patient inclusion and prepared Figs. 1, 2, 4 and 5; Table 1 and supplement material S1-8. E.M. performed measurements and patient inclusion F.T. performed statistical analysis, wrote statistical analysis, prepared Figs 1, 2, 3, 4 and 5, Table 1, supplement S8. F.H. designed study All authors reviewed the manuscript.
Corresponding author
Correspondence to Mavi Schellenberg.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
This study was reviewed and approved by the Ethics Committee of University of Heidelberg, Prof. Dr. med. Dr. h.c. Thomas Strowitzki, (reference number: DE-24-00015155, committee: Mzmo-053/2024). All research activities were conducted in accordance with the ethical principles of the Declaration of Helsinki. Participation in the study was voluntary, and all participants provided written informed consent.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Schellenberg, M., Mbi-Etah, E., Trinkmann, F. et al. Handheld volumetric capnography (Lumetry) for carbon dioxide monitoring in advanced COPD. Sci Rep 16, 38207 (2026). https://doi.org/10.1038/s41598-026-80296-5
Received: 13 March 2026
Accepted: 06 November 2026
Published: 16 November 2026
Version of record: 16 November 2026
DOI: https://doi.org/10.1038/s41598-026-80296-5
Keywords
来源:Nature 健康护理主题 · nature.com